Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 8/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 4/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3003868 | 0.94 | BMP1 (0.40) | VCAM1TXNRD1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL3015351 | 0.93 | MAPT (0.39) | VCAM1TXNRD1ALDH1A1LMNAMAPT | |
| SCHEMBL3016253 | 0.91 | VCAM1 (0.37) | VCAM1TXNRD1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL3009108 | 0.90 | VCAM1 (0.40) | VCAM1TXNRD1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL3014057 | 0.90 | MAPT (0.37) | MCHR1ALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL3003703 | 0.89 | VCAM1 (0.40) | VCAM1TXNRD1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL3014231 | 0.89 | RAB9A (0.40) | VCAM1TXNRD1ALDH1A1LMNAMAPT | |
| SCHEMBL3014774 | 0.88 | VCAM1 (0.40) | VCAM1NPBWR1MCHR1ALDH1A1LMNA | |
| SCHEMBL3012038 | 0.88 | VCAM1 (0.40) | VCAM1NPBWR1MCHR1ALDH1A1LMNA | |
| SCHEMBL3016965 | 0.88 | VCAM1 (0.49) | VCAM1NPBWR1MCHR1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | VCAM1 3154/4885TXNRD1 137/4885NPBWR1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.